Literature DB >> 3592119

N-myc oncogene amplification in a patient with IV-S neuroblastoma.

G P Tonini, G Verdona, B De Bernardi, R Sansone, L Massimo, P Cornaglia-Ferraris.   

Abstract

Neuroblastoma (NB) is a tumor usually arising in children and young adults showing different degrees of malignancy. Recently, the presence of N-myc amplification in neuroblasts has been associated with a poor outcome in the late stages of disease (Evans's Stage IV). Until now no amplification of N-myc gene has been observed in Stage IV-S, usually considered to have a favorable prognosis. In this paper we report a case of a child affected by NB Stage IV-S showing mild N-myc gene amplification. The finding of N-myc amplification in our patient shows that such alteration of the N-myc oncogene is not necessarily correlated with a poor prognosis; in this light the role of N-myc amplification in the neoplastic process should be reconsidered.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3592119     DOI: 10.1097/00043426-198721000-00002

Source DB:  PubMed          Journal:  Am J Pediatr Hematol Oncol        ISSN: 0192-8562


  3 in total

1.  Evidence of apoptosis in neuroblastoma at onset and relapse. An analysis of a large series of tumors.

Authors:  G P Tonini; K Mazzocco; A di Vinci; E Geido; B de Bernardi; W Giaretti
Journal:  J Neurooncol       Date:  1997-01       Impact factor: 4.130

2.  Different regulation of mid-size neurofilament and N-myc mRNA expression during neuroblastoma cell differentiation induced by retinoic acid.

Authors:  D Di Martino; M Ponzoni; P Cornaglia-Ferraris; G P Tonini
Journal:  Cell Mol Neurobiol       Date:  1990-09       Impact factor: 5.046

3.  Comparative genomic hybridization and telomerase activity analysis identify two biologically different groups of 4s neuroblastomas.

Authors:  C Brinkschmidt; C Poremba; H Christiansen; R Simon; K L Schäfer; H J Terpe; F Lampert; W Boecker; B Dockhorn-Dworniczak
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.